BCG022 / Biocytogen, Doma Pharma - LARVOL DELTA

BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy (AACR 2024) - "Both demonstrated strong anti-tumor activity, with efficacy greater than or comparable to benchmark ADCs. Taken together, these promising preclinical results suggest that the BCG022 bsADC could be a novel treatment for HER3 and MET co-expressing tumors."

Clinical • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ERBB3 • MET

BCG022: a HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types (SITC 2023) - "Lastly, BCG022 candidates demonstrated enhanced anti-tumor activity in vivo compared with benchmark and parental Ab-ADCs in PDX models. Conclusions Collectively, these results suggest that BCG022 has the potential to be a novel therapeutic option for HER3 and MET co-expressing tumors."

Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ERBB3

Biocytogen Announces 16 Poster Presentations and Booth Exhibition at SITC 2023 (Businesswire) - "Biocytogen Pharmaceuticals (Beijing) Co., Ltd...announced today that the company will be presenting 16 posters and exhibiting at booth 223 at the Society for Immunotherapy of Cancer (SITC) annual conference, taking place from November 1-5, 2023 in San Diego, CA."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer